Stock

Albemarle Corporation

ALB

Chemicals - Specialty · Basic Materials

Also trades as: 0HC7.L GBP 0.94 (+1.83%)

Price

$93.67

+1.13 (+1.22%)

Market Cap

$11.05B

Winston Score

Winston is curious

Mixed quality — meaningful strengths and weaknesses.

Data as of Oct 24, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality

Mixed

14/30

Growth

Good

11/20

Cash Flow

Exceptional

10/10

Stability

Strong

8/10

Valuation

Good

5/10

Ownership

Weak

2/15

Dividends

Weak

1/5

51 of 100 counted points = Winston Score 51.

Track this stock — start free trial

§Winston Score History

The full picture

Albemarle is a chemical company that mines and processes lithium, bromine, and other specialty chemicals. Its biggest business is lithium, which is a key ingredient in the batteries that power electric vehicles and smartphones. The company sells to battery makers, automakers, and industrial manufacturers around the world.

Albemarle makes money by selling these processed chemicals directly to manufacturers under long-term contracts and on the open market. It operates globally, with major assets in Chile, Australia, and the United States, making it one of the largest lithium producers in the world. The company's main growth driver is demand for electric vehicle batteries, but its biggest risk is lithium price volatility — prices collapsed sharply after 2022, which is why margins and returns on capital are currently low.

Politician Trades

6 trades / 12mo

3 Congressional buys and 3 sells on ALB in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+31.1% YoY

YoY Growth Rate

Revenue accelerating

Reported EPS Growth

>+1,000% YoY

Quarterly reporting periods ended:

30 Jun 2025: $-0.16

30 Jun 2026: $3.72

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$51M/ year

↓ Declining (-41% vs prior year)

1.0% of revenue

Below sector average (3%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$2.7B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Albemarle Corporation grew revenue 31% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+1.0% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 116.5M (2021) → 117.7M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

33.9%

Modest — 33.9% gross margin

Profit after running costs

Operating Margin

26.0%

Excellent — 26.0% operating margin

Return on the money invested

ROCE

5.7%

Weak — 5.7% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+18.3%

Fast-growing sales (+18.3% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

803%

Turns 803% of profit into real cash

Spare cash per sale

FCF Margin

22.7%

Converts sales into free cash efficiently (22.7%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.19

Conservative — low debt load (0.19)

Covers its interest

Interest Cover

4.08x

Adequate interest coverage (4.1x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

195.1x

Expensive — P/E 195.1

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+156.5

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (195.1 → 38.7)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend

Dividend Yield

1.60%

Small dividend — 1.60% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record

Dividend Growth

+0.3%

Dividend flat

Payout Ratio

159%

no trend

Paying out more than the last 12 months of profit. The dividend is being funded from cash or borrowing, not this year’s earnings.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial